Cargando…
MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway
BACKGROUND: CB(2) (cannabinoid receptor 2) agonists have been shown to exert anti-tumor activities in different tumor types. However, there is no study exploring the role of MDA19 (a novel CB(2) agonist) in tumors. In this study we aimed to investigate the effects of MDA19 treatment on HCC cell line...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500002/ https://www.ncbi.nlm.nih.gov/pubmed/31053086 http://dx.doi.org/10.1186/s13062-019-0241-1 |